We chose to work on BRCA2-associated pancreatic cancer, not only because BRCA2 mutation carriers have higher susceptibility to this disease, but also because we could leverage earlier work by Dave Tuveson and Tyler Jacks, in order to create a new model for familial pancreatic cancer in my lab. The gene discussed is BRCA2; the disease is pancreatic neoplasm.